Although PPARβ agonists are not yet in clinical use, human studies have been performed to test the efficacy of two compounds, GW501516 and MBX-8025, providing very encouraging findings for the treatment of metabolic disorders in dyslipidemic obese individuals32, 33, 34, 35, 36. This evidence concerns the gene PPARD and metabolic disease.